Form 4: Supernus Pharmaceuticals CEO Jack A. Khattar Reports Stock Option Grant
SEC Form 4 Filing
Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, reports the acquisition of stock options.
Summary
- Jack A. Khattar, the President and CEO of Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates that on February 20, 2025, Khattar acquired 331,660 employee stock options with an exercise price of $34.59.
- These options vest in four equal annual installments starting on February 19, 2026, and expire on February 20, 2035.
- Khattar directly owns 953,579 shares of common stock and indirectly owns 1,022,450 shares through the KBT Trust.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The size and vesting schedule of the grant are typical considerations.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their leadership teams.
- The vesting schedules and exercise prices are generally determined based on company performance and industry benchmarks.
Stakeholder Impact
- The stock option grant could positively impact shareholders by incentivizing the CEO to improve company performance.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of transaction: Grant of employee stock options. |
| 02/19/2026 | First vesting date for the employee stock options. |
| 02/20/2035 | Expiration date of the employee stock options. |
Keywords
Supernus Pharmaceuticals, Jack A. Khattar, stock options, Form 4, beneficial ownership, CEO, SUPN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.